Outlook Therapeutics Inc OTLK

NAS: OTLK | ISIN: US69012T2069   30/04/2025
1,570 USD (+0,64%)
(+0,64%)   30/04/2025
Grafiek Outlook Therapeutics Inc Grafiek Outlook Therapeutics Inc

Outlook Therapeutics Inc in het nieuws

4 december 2024 · Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD · Persbericht

8 juli 2024 · Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD · Persbericht

28 december 2023 · OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

28 december 2023 · OUTLOOK INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options · Persbericht

21 december 2023 · OUTLOOK INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options · Persbericht

14 december 2023 · OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

5 december 2023 · OUTLOOK SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options · Persbericht

13 november 2023 · Outlook Investor Deadline Approaching · Persbericht

13 november 2023 · SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Outlook Investors of a Lead Plaintiff Deadline of January 2, 2024 · Persbericht

11 november 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OTLK · Persbericht

Profiel Outlook Therapeutics Inc

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: outlooktherapeutics.com

Hoofdzetel: Monmouth Junction, New Jersey vlag Verenigde Staten

CEO: Lawrence Kenyon

Werknemers: 18

Mijn selecties